The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
Check out some of NeurologyLive®'s featured content in the carousel below.
COVID-19 and the Brain: Understanding the Neurological Effects of the Virus as the Pandemic Evolves
December 16th 2022Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.
Integrating Machine Learning, Digital Platforms to Alzheimer Trials: David Bates, PhD
December 15th 2022The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]
Significance of ALZ-801’s Impact on Carriers of APOE e4 Alleles: Susan Abushakra, MD
December 13th 2022The chief medical officer of Alzheon discussed the impact a therapy like ALZ-801 can have on the overall Alzheimer community considering its effects on carriers of APOE e4 alleles. [WATCH TIME: 3 minutes]
Hydromethylthionine Mesylate’s Place as a Potential Tau Aggregator of Alzheimer Disease
December 13th 2022Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.
Fueling Research Focused on Improving Diagnosis and Therapeutics in Alzheimer Disease
December 12th 2022Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.
Continuing to Advance Alzheimer Clinical Trial Design Through Technology: David Bates, PhD
December 12th 2022The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]
Building the Biomarker Panel in Neurology: Glial Fibrillary Acidic Protein
December 9th 2022As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.
Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays
December 9th 2022The Elecsys pTau181 and Abeta42 cerebrospinal fluid assays achieved 90% concordance with amyloid PET scans, according to Roche’s announcement. The assays are approved for use with the cobas fully automated immunoassay analyzers.
Therapeutic Potential of ALZ-801 in High-Risk Alzheimer Disease: Susan Abushakra, MD
December 8th 2022The chief medical officer of Alzheon provided perspective on new phase 2 findings assessing the investigational agent ALZ-801 in patients with early Alzheimer disease and a genetic predisposition. [WATCH TIME: 5 minutes]
Ultraprocessed Food Consumption Association With Increased Risk of Cognitive Decline
December 8th 2022Percentage of daily energy from ultraprocessed food was associated with cognitive decline in participants younger than 60 years, suggesting the importance of preventive interventions in middle-aged adults.
Reimaging the Approach to Treating Alzheimer Agitation: Sube Banerjee, MD, MSc, MBA, FRCPsych
December 7th 2022The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the way to attack Alzheimer agitation and why drug solutions often fall short. [WATCH TIME: 3 minutes]
Expanding the Pathways to Treat Dementia With Lewy Bodies: James Galvin, MD, MPH
December 7th 2022The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]
Working Towards Lowering ARIA Rates, Reducing Amyloid Plaques: Marwan Sabbagh, MD, FAAN
December 7th 2022The behavioral neurologist at the Barrow Neurological Institute detailed the significance of low rates of ARIA found in lecanemab, and the direction of anti-amyloid therapies in the future. [WATCH TIME: 4 minutes]
Understanding the Safety Profile of Lecanamab: Marwan Sabbagh, MD, FAAN
December 3rd 2022The behavioral neurologist at the Barrow Neurological Institute provided perspective on the safety profile of lecanemab and the importance of a low incidence of amyloid-related imaging abnormalities. [WATCH TIME: 3 minutes]
Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH
December 2nd 2022The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies and Alzheimer disease. [WATCH TIME: 4 minutes]